Literature DB >> 8504424

Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy.

R Zhang1, Z Lu, T Liu, S J Soong, R B Diasio.   

Abstract

Previous studies in experimental animals and patients have suggested a circadian variation in host toxicity following administration of 5-fluorodeoxyuridine (FdUrd) although the biochemical mechanisms are not fully understood. Thymidine kinase (TK; EC 2.7.1.21), the initial enzyme in the thymidine-phosphorylation pathway, is the first enzyme in the anabolism of FdUrd. Dihydropyrimidine dehydrogenase (DPD; EC 1.3.1.2), is the rate-limiting enzyme in the pyrimidine catabolic pathway and has been shown to be the key enzyme in FdUrd catabolism. The present study examined the relationship between the suggested circadian variation in FdUrd toxicity and potential circadian variations in the activity of these enzymes. Initial studies in Sprague-Dawley rats confirmed that the time of FdUrd administration affected death rate and other drug-related toxicities including loss of body weight, diarrhea, and bone marrow suppression, with the least toxicity and highest survival rate being observed in rats receiving FdUrd at 12:00 noon and 4:00 p.m. and the greatest toxicity and lowest survival rate at 12:00 midnight and 4:00 a.m. Statistical analysis revealed a circadian pattern in FdUrd toxicity (Cosinor analysis, P < 0.001). In subsequent studies with the same species, we simultaneously measured TK and DPD activities in several tissues at various times over 24 h. Under standardized light conditions (lights on, 6:00 a.m. to 6:00 p.m.; lights off, 6:00 p.m. to 6:00 a.m.), with sampling at 4-h intervals (4:00 and 8:00 a.m.; 12:00 noon; 4:00 and 8:00 p.m., and 12:00 midnight), a circadian variation in TK activity was observed (P < 0.0001, Cosinor analysis) in bone marrow, intestinal mucosa, liver, and spleen. In the same group of animals, a circadian pattern of DPD activity in liver and bone marrow was also observed (Cosinor analysis, P < 0.0001) that was inverse compared to the circadian variation in TK activity (Pearson correlation analysis, P < 0.05). Further statistical analysis indicated that the observed circadian variation in FdUrd toxicity was correlated with the circadian variation of TK activity and inversely correlated with DPD activity (Pearson correlation analysis, P < 0.05). Based on the above data, we conclude that the circadian pattern of TK and DPD activity may explain the observed circadian variation in toxicity as the time of FdUrd administration is varied. These results may be useful in the design of improved chemotherapeutic regimens using time-modified administration of FdUrd.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8504424

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Tissue disposition of zidovudine and its phosphorylated metabolites in zidovudine-treated healthy and retrovirus infected mice.

Authors:  H H Chow; G Brookshier; P Li
Journal:  Pharm Res       Date:  1998-01       Impact factor: 4.200

2.  The efficacy of a modified chronomodulated infusion of oxaliplatin, 5-fluorouracil and leucovorin in advanced colorectal cancer (preliminary data).

Authors:  Ji Young Park; Si-Young Kim; Jae Jin Lee; Hwi Joong Yoon; Kyung Sam Cho
Journal:  Cancer Res Treat       Date:  2004-06-30       Impact factor: 4.679

Review 3.  Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action.

Authors:  Siddharth Sukumaran; Richard R Almon; Debra C DuBois; William J Jusko
Journal:  Adv Drug Deliv Rev       Date:  2010-06-11       Impact factor: 15.470

Review 4.  The oral fluorinated pyrimidines.

Authors:  J S de Bono; C J Twelves
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

5.  The time of administration of 3'-azido-3'-deoxythymidine (AZT) determines its host toxicity with possible relevance to AZT chemotherapy.

Authors:  R Zhang; Z Lu; C R Diasio; T Liu; S J Soong
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

6.  A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule.

Authors:  Marie-Christine Etienne-Grimaldi; Eric François; Jean-Michel Cardot; Nicole Renée; Jean-Yves Douillard; Erick Gamelin; Jaafar Bennouna; Yann Château; Gérard Milano
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

7.  Pharmacokinetic interaction of 5-fluorouracil and interferon alpha-2b with or without folinic acid.

Authors:  J b1p6uller; M Czejka
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

8.  Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in metastatic adenocarcinoma patients.

Authors:  G A Bjarnason; I G Kerr; N Doyle; M Macdonald; M Sone
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels.

Authors:  Hao Jiang; Jing Lu; Jiang Ji
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

Review 10.  Circadian clock genes as modulators of sensitivity to genotoxic stress.

Authors:  Marina P Antoch; Roman V Kondratov; Joseph S Takahashi
Journal:  Cell Cycle       Date:  2005-07-26       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.